Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 2
1977 2
1978 6
1979 1
1980 1
1981 2
1982 3
1983 3
1984 2
1986 1
1987 2
1988 1
1989 2
1990 5
1991 11
1992 4
1993 6
1994 7
1995 7
1996 3
1997 4
1998 4
1999 5
2000 2
2001 4
2002 1
2003 1
2004 2
2005 2
2006 1
2007 1
2008 2
2012 3
2013 4
2014 2
2018 1
2019 2
2024 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Did you mean geniposide (4 results)?
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.
Bromberg JEC, Issa S, van der Holt B, van der Meulen M, Dirven L, Minnema MC, Seute T, Durian M, Cull G, van der Poel MWM, Stevens WBC, Zijlstra JM, Brandsma D, Nijland M, Mason KD, Beeker A, Abrahamse-Testroote MCJ, van den Bent MJ, de Jong D, Doorduijn JK. Bromberg JEC, et al. Neuro Oncol. 2024 Apr 5;26(4):724-734. doi: 10.1093/neuonc/noad224. Neuro Oncol. 2024. PMID: 38037691 Free PMC article. Clinical Trial.
Our international randomized phase 3 study showed that the addition of rituximab to high-dose methotrexate, BCNU, teniposide, and prednisolone (MBVP) in PCNSL was not efficacious in the short term. Here we present long-term results after a median follow-up of 82.3 months. …
Our international randomized phase 3 study showed that the addition of rituximab to high-dose methotrexate, BCNU, teniposide, and pre …
Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study.
Bork E, Ersbøll J, Dombernowsky P, Bergman B, Hansen M, Hansen HH. Bork E, et al. J Clin Oncol. 1991 Sep;9(9):1627-31. doi: 10.1200/JCO.1991.9.9.1627. J Clin Oncol. 1991. PMID: 1651994 Clinical Trial.
A randomized study comparing teniposide (VM-26) and etoposide (VP-16) was performed to investigate whether there are any differences in the activity and toxicity of these two analogs in small-cell lung cancer (SCLC). ...
A randomized study comparing teniposide (VM-26) and etoposide (VP-16) was performed to investigate whether there are any differences …
Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial.
Wu J, Duan L, Zhang L, Sun Z, Fu X, Li X, Li L, Wang X, Zhang X, Li Z, Yu H, Chang Y, Nan F, Yan J, Tian L, Wang X, Zhang M. Wu J, et al. J Neurooncol. 2018 Nov;140(2):427-434. doi: 10.1007/s11060-018-2970-x. Epub 2018 Aug 14. J Neurooncol. 2018. PMID: 30109672 Free PMC article. Clinical Trial.
OBJECTIVE: This prospective, randomized, controlled and open-label clinical trial sought to evaluate the tolerability and efficacy of the FTD regimen (fotemustine, teniposide and dexamethasone) compared to HD-MA therapy (high-dose methotrexate plus cytarabine) and to eluci …
OBJECTIVE: This prospective, randomized, controlled and open-label clinical trial sought to evaluate the tolerability and efficacy of the FT …
Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588).
Ettinger DS, Finkelstein DM, Ritch PS, Lincoln ST, Blum RH; Eastern Cooperative Oncology Group. Ettinger DS, et al. Lung Cancer. 2002 Sep;37(3):311-8. doi: 10.1016/s0169-5002(02)00074-0. Lung Cancer. 2002. PMID: 12234701 Clinical Trial.
The estimated median survival time was 42 weeks for CAV patients, 43 weeks for ifosfamide, and 38 weeks for teniposide. Seven patients survived longer than 2 years (four on CAV, one on ifosfamide and two on teniposide). There were 29 life-threatening complications t …
The estimated median survival time was 42 weeks for CAV patients, 43 weeks for ifosfamide, and 38 weeks for teniposide. Seven patient …
Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients.
Rodman JH, Sunderland M, Kavanagh RL, Ochs J, Yalowich J, Evans WE, Rivera GK. Rodman JH, et al. Cancer Res. 1990 Jul 15;50(14):4267-71. Cancer Res. 1990. PMID: 2194652 Clinical Trial.
Patients were randomly assigned to receive intermediate dose methotrexate as a 24-h continuous infusion, administered either simultaneously with continuous infusion teniposide or sequentially with the teniposide infusion beginning 12 h after the end of the methotrex …
Patients were randomly assigned to receive intermediate dose methotrexate as a 24-h continuous infusion, administered either simultaneously …
Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group.
Postmus PE, Haaxma-Reiche H, Smit EF, Groen HJ, Karnicka H, Lewinski T, van Meerbeeck J, Clerico M, Gregor A, Curran D, Sahmoud T, Kirkpatrick A, Giaccone G. Postmus PE, et al. J Clin Oncol. 2000 Oct 1;18(19):3400-8. doi: 10.1200/JCO.2000.18.19.3400. J Clin Oncol. 2000. PMID: 11013281 Clinical Trial.
PATIENTS AND METHODS: In a phase III study, SCLC patients with brain metastases were randomized to receive teniposide with or without WBRT. Teniposide 120 mg/m(2) was given intravenously three times a week, every 3 weeks. ...The median survival time was 3.5 months i …
PATIENTS AND METHODS: In a phase III study, SCLC patients with brain metastases were randomized to receive teniposide with or without …
[Radiotherapy of malignant brain gliomas using teniposide].
Mufazalov FF, Sakaeva DD, Shtefan AIu. Mufazalov FF, et al. Vopr Onkol. 2008;54(2):208-10. Vopr Onkol. 2008. PMID: 18522171 Clinical Trial. Russian.
Efficacy of radiochemotherapy of malignantly-converted brain gliomas using teniposide was evaluated in a randomized prospective study. Combined use of cytostatics and irradiation appeared safe, tolerable and significantly more effective than radiotherapy alone as assessed …
Efficacy of radiochemotherapy of malignantly-converted brain gliomas using teniposide was evaluated in a randomized prospective study …
Phase II study of PALA, amsacrine, teniposide, and zinostatin in small cell lung carcinoma (EST 2579).
Creech RH, Tritchler D, Ettinger DS, Ferraro JA, Ruckdeschel JC, Vogl SE, Woll J. Creech RH, et al. Cancer Treat Rep. 1984 Sep;68(9):1183-4. Cancer Treat Rep. 1984. PMID: 6090017 Clinical Trial.
Eighty-two patients with small cell lung carcinoma refractory to standard chemotherapy were entered in this phase II randomized study of PALA, amsacrine, teniposide, and zinostatin. Of the 66 evaluable patients, one partial response occurred among 17 patients treated with …
Eighty-two patients with small cell lung carcinoma refractory to standard chemotherapy were entered in this phase II randomized study of PAL …
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA, Alberto P, Hürny C, Bacchi M, Leyvraz S, Thürlimann B, Cerny T, Martinelli G, Stahel R, Ludwig C. Joss RA, et al. Ann Oncol. 1995 Jan;6(1):41-8. doi: 10.1093/oxfordjournals.annonc.a059039. Ann Oncol. 1995. PMID: 7536028 Free article. Clinical Trial.
BACKGROUND: Based on a promising pilot study with weekly carboplatin and teniposide (CBDCA/VM) the Swiss Group for Clinical Cancer Research (SAKK) performed a randomised phase III trial in patients with extensive-disease small-cell lung cancer aimed at the development of a …
BACKGROUND: Based on a promising pilot study with weekly carboplatin and teniposide (CBDCA/VM) the Swiss Group for Clinical Cancer Re …
Cyclophosphamide/doxorubicin vs. cisplatin/teniposide in the treatment of children older than 12 months of age with disseminated neuroblastoma: a Pediatric Oncology Group Randomized Phase II study.
McWilliams NB, Hayes FA, Green AA, Smith EI, Nitschke R, Altshuler GA, Shuster JJ, Castleberry RP, Vietti TJ. McWilliams NB, et al. Med Pediatr Oncol. 1995 Mar;24(3):176-80. doi: 10.1002/mpo.2950240307. Med Pediatr Oncol. 1995. PMID: 7838039 Clinical Trial.
This prospective study was designed to estimate the response rates and to compare two drug pairs, cyclophosphamide/doxorubicin (Cy/A) and cisplatin/teniposide (P1/VM) in previously untreated patients with disseminated neuroblastoma > 12 months of age at diagnosis. ...
This prospective study was designed to estimate the response rates and to compare two drug pairs, cyclophosphamide/doxorubicin (Cy/A) and ci …
111 results